 Todd Kingdom
Concepts (344)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 24 | 2021 | 175 | 4.000 |
Why?
| | Rhinitis | 22 | 2023 | 128 | 3.650 |
Why?
| | Nasal Polyps | 15 | 2017 | 49 | 3.330 |
Why?
| | Endoscopy | 19 | 2023 | 247 | 2.800 |
Why?
| | Paranasal Sinuses | 13 | 2017 | 66 | 2.090 |
Why?
| | Dacryocystorhinostomy | 3 | 2020 | 10 | 1.160 |
Why?
| | Surgery, Computer-Assisted | 3 | 2015 | 63 | 1.100 |
Why?
| | Nasal Mucosa | 6 | 2019 | 95 | 1.060 |
Why?
| | Paranasal Sinus Neoplasms | 5 | 2024 | 17 | 1.030 |
Why?
| | Skull Base | 6 | 2023 | 39 | 0.980 |
Why?
| | Aspirin | 6 | 2016 | 327 | 0.970 |
Why?
| | Orbit | 4 | 2016 | 59 | 0.770 |
Why?
| | Cystic Fibrosis | 6 | 2014 | 961 | 0.750 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2015 | 301 | 0.650 |
Why?
| | Lipoxygenase | 2 | 2008 | 12 | 0.600 |
Why?
| | Postoperative Complications | 6 | 2018 | 2167 | 0.590 |
Why?
| | Chronic Disease | 18 | 2023 | 1602 | 0.570 |
Why?
| | Sphenoid Sinus | 2 | 2009 | 8 | 0.570 |
Why?
| | Asthma, Aspirin-Induced | 1 | 2015 | 1 | 0.530 |
Why?
| | Decompression, Surgical | 2 | 2017 | 93 | 0.510 |
Why?
| | Graves Ophthalmopathy | 1 | 2015 | 14 | 0.500 |
Why?
| | Paranasal Sinus Diseases | 3 | 2017 | 14 | 0.480 |
Why?
| | Protein Array Analysis | 2 | 2011 | 61 | 0.420 |
Why?
| | Eosinophilia | 3 | 2016 | 187 | 0.420 |
Why?
| | Respiratory System | 1 | 2013 | 141 | 0.410 |
Why?
| | Bronchiectasis | 1 | 2013 | 108 | 0.410 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 23 | 0.400 |
Why?
| | Middle Aged | 30 | 2019 | 27083 | 0.390 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 213 | 0.390 |
Why?
| | Immunotherapy | 1 | 2015 | 480 | 0.390 |
Why?
| | Sputum | 1 | 2013 | 291 | 0.390 |
Why?
| | Tomography, X-Ray Computed | 15 | 2018 | 2408 | 0.390 |
Why?
| | Rhinitis, Allergic | 4 | 2021 | 37 | 0.380 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 118 | 0.380 |
Why?
| | Chemokine CCL5 | 1 | 2011 | 48 | 0.380 |
Why?
| | Humans | 68 | 2024 | 115900 | 0.370 |
Why?
| | Evidence-Based Medicine | 5 | 2016 | 686 | 0.360 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 21 | 0.360 |
Why?
| | Frontal Sinus | 2 | 2007 | 4 | 0.350 |
Why?
| | Retrospective Studies | 22 | 2022 | 12616 | 0.350 |
Why?
| | Surgical Flaps | 3 | 2019 | 121 | 0.350 |
Why?
| | Cerebrospinal Fluid Rhinorrhea | 3 | 2022 | 7 | 0.350 |
Why?
| | Leiomyosarcoma | 1 | 2009 | 24 | 0.340 |
Why?
| | Adult | 29 | 2019 | 30817 | 0.340 |
Why?
| | Cyclooxygenase 2 | 2 | 2008 | 165 | 0.330 |
Why?
| | Mycoses | 3 | 2005 | 67 | 0.330 |
Why?
| | Odontoma | 1 | 2008 | 4 | 0.320 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2008 | 7 | 0.320 |
Why?
| | Head and Neck Neoplasms | 3 | 2024 | 425 | 0.320 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2008 | 59 | 0.320 |
Why?
| | Male | 37 | 2023 | 56126 | 0.300 |
Why?
| | Aged | 22 | 2019 | 19299 | 0.290 |
Why?
| | Immunoglobulin E | 2 | 2018 | 363 | 0.290 |
Why?
| | Female | 34 | 2023 | 60081 | 0.270 |
Why?
| | Treatment Outcome | 12 | 2023 | 9165 | 0.270 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2007 | 72 | 0.270 |
Why?
| | Nose Neoplasms | 2 | 1996 | 15 | 0.270 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1403 | 0.260 |
Why?
| | Consensus | 3 | 2021 | 533 | 0.260 |
Why?
| | Osteomyelitis | 1 | 2007 | 105 | 0.250 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 17 | 0.250 |
Why?
| | Antibiotic Prophylaxis | 2 | 2016 | 96 | 0.250 |
Why?
| | Streptococcus | 1 | 2004 | 23 | 0.240 |
Why?
| | Prednisone | 2 | 2017 | 232 | 0.240 |
Why?
| | Gram-Negative Bacteria | 1 | 2004 | 67 | 0.240 |
Why?
| | Staphylococcus | 1 | 2004 | 69 | 0.240 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 4 | 2011 | 33 | 0.230 |
Why?
| | Hypersensitivity | 3 | 2024 | 272 | 0.230 |
Why?
| | Adenoma | 2 | 2018 | 187 | 0.230 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2003 | 14 | 0.220 |
Why?
| | Skull Base Neoplasms | 1 | 2023 | 26 | 0.220 |
Why?
| | Bone Diseases | 1 | 2003 | 58 | 0.210 |
Why?
| | Reoperation | 3 | 2019 | 526 | 0.210 |
Why?
| | Aged, 80 and over | 10 | 2018 | 6438 | 0.200 |
Why?
| | Pseudomonas aeruginosa | 4 | 2014 | 303 | 0.200 |
Why?
| | Adolescent | 13 | 2019 | 17956 | 0.200 |
Why?
| | Laryngeal Diseases | 2 | 2003 | 19 | 0.190 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2020 | 4 | 0.190 |
Why?
| | Nasolacrimal Duct | 1 | 2020 | 7 | 0.190 |
Why?
| | Glucocorticoids | 2 | 2017 | 551 | 0.190 |
Why?
| | Diagnosis, Differential | 4 | 2018 | 1358 | 0.170 |
Why?
| | Nasal Septum | 2 | 2020 | 16 | 0.170 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 4 | 0.170 |
Why?
| | Otolaryngology | 2 | 2011 | 71 | 0.170 |
Why?
| | Sella Turcica | 1 | 2018 | 12 | 0.160 |
Why?
| | Polyethylenes | 1 | 2018 | 16 | 0.160 |
Why?
| | Parotid Diseases | 1 | 1998 | 4 | 0.160 |
Why?
| | Ethmoid Sinus | 2 | 2015 | 7 | 0.160 |
Why?
| | Sclerosing Solutions | 1 | 1998 | 9 | 0.160 |
Why?
| | Up-Regulation | 2 | 2012 | 824 | 0.160 |
Why?
| | Sclerotherapy | 1 | 1998 | 19 | 0.160 |
Why?
| | Vision Disorders | 2 | 2017 | 130 | 0.160 |
Why?
| | Doxycycline | 1 | 1998 | 56 | 0.160 |
Why?
| | Immunohistochemistry | 3 | 2009 | 1643 | 0.150 |
Why?
| | Immunoglobulin D | 1 | 2017 | 28 | 0.150 |
Why?
| | Melanoma | 2 | 1995 | 649 | 0.150 |
Why?
| | Cysts | 1 | 1998 | 94 | 0.150 |
Why?
| | Mucocele | 1 | 2017 | 11 | 0.150 |
Why?
| | Follow-Up Studies | 4 | 2015 | 4446 | 0.150 |
Why?
| | Prostheses and Implants | 1 | 2018 | 141 | 0.150 |
Why?
| | Pituitary Neoplasms | 1 | 2018 | 157 | 0.150 |
Why?
| | Visual Acuity | 2 | 2017 | 273 | 0.140 |
Why?
| | Aspergillus fumigatus | 1 | 1996 | 20 | 0.140 |
Why?
| | Aspergillosis | 1 | 1996 | 24 | 0.140 |
Why?
| | Young Adult | 8 | 2018 | 10517 | 0.140 |
Why?
| | Neuroendoscopy | 1 | 2016 | 14 | 0.130 |
Why?
| | Rhinitis, Allergic, Perennial | 2 | 2013 | 24 | 0.130 |
Why?
| | Therapeutic Irrigation | 1 | 2016 | 65 | 0.130 |
Why?
| | Graves Disease | 1 | 2016 | 32 | 0.130 |
Why?
| | Th1-Th2 Balance | 1 | 2015 | 10 | 0.130 |
Why?
| | Superantigens | 1 | 2015 | 69 | 0.130 |
Why?
| | Pharynx | 1 | 1995 | 49 | 0.130 |
Why?
| | Mouth | 1 | 1995 | 68 | 0.130 |
Why?
| | Nasopharynx | 1 | 2015 | 63 | 0.130 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1996 | 117 | 0.130 |
Why?
| | Neck | 3 | 2005 | 85 | 0.130 |
Why?
| | Forced Expiratory Volume | 2 | 2014 | 522 | 0.130 |
Why?
| | Nasal Cavity | 1 | 1995 | 47 | 0.120 |
Why?
| | Biocompatible Materials | 1 | 2018 | 379 | 0.120 |
Why?
| | Meningitis | 1 | 2016 | 74 | 0.120 |
Why?
| | Dinoprostone | 1 | 2015 | 188 | 0.120 |
Why?
| | Intraoperative Complications | 1 | 2016 | 126 | 0.120 |
Why?
| | Actinomycosis | 1 | 1994 | 4 | 0.120 |
Why?
| | Cervical Vertebrae | 1 | 1995 | 104 | 0.120 |
Why?
| | Neurosurgical Procedures | 1 | 2016 | 157 | 0.120 |
Why?
| | Radiotherapy, Adjuvant | 1 | 1995 | 182 | 0.120 |
Why?
| | Nose Diseases | 1 | 1994 | 11 | 0.120 |
Why?
| | Microbiota | 3 | 2018 | 651 | 0.120 |
Why?
| | Case-Control Studies | 5 | 2017 | 3056 | 0.120 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2017 | 340 | 0.120 |
Why?
| | Angiofibroma | 1 | 2013 | 3 | 0.120 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2013 | 14 | 0.110 |
Why?
| | Pituitary Diseases | 1 | 2013 | 22 | 0.110 |
Why?
| | Cerebellopontine Angle | 1 | 1993 | 6 | 0.110 |
Why?
| | Granulocytes | 1 | 2013 | 78 | 0.110 |
Why?
| | HIV Seropositivity | 1 | 1994 | 110 | 0.110 |
Why?
| | Biopsy | 3 | 2017 | 1056 | 0.110 |
Why?
| | Biofilms | 1 | 2015 | 222 | 0.110 |
Why?
| | Prospective Studies | 3 | 2012 | 6267 | 0.110 |
Why?
| | bcl-X Protein | 1 | 2012 | 39 | 0.110 |
Why?
| | Transforming Growth Factor beta | 1 | 2015 | 447 | 0.110 |
Why?
| | Chemoreceptor Cells | 1 | 2013 | 53 | 0.110 |
Why?
| | Microarray Analysis | 1 | 2012 | 120 | 0.100 |
Why?
| | Vital Capacity | 1 | 2013 | 279 | 0.100 |
Why?
| | Cerebrospinal Fluid Leak | 3 | 2022 | 28 | 0.100 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 67 | 0.100 |
Why?
| | Neoplasms, Second Primary | 2 | 2012 | 91 | 0.100 |
Why?
| | Skull Neoplasms | 1 | 2012 | 21 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2013 | 862 | 0.100 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 283 | 0.100 |
Why?
| | Cerebellar Neoplasms | 1 | 1993 | 131 | 0.100 |
Why?
| | Histocytochemistry | 1 | 2011 | 78 | 0.100 |
Why?
| | Incidence | 2 | 2015 | 2333 | 0.100 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2014 | 288 | 0.100 |
Why?
| | Pituitary Gland | 1 | 2012 | 152 | 0.090 |
Why?
| | Vasoconstrictor Agents | 1 | 2011 | 113 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 6 | 2013 | 3086 | 0.090 |
Why?
| | Bacteria | 1 | 2016 | 731 | 0.090 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 403 | 0.090 |
Why?
| | Adaptor Protein Complex beta Subunits | 1 | 2009 | 1 | 0.090 |
Why?
| | Caspase 8 | 1 | 2009 | 43 | 0.080 |
Why?
| | Caspase 9 | 1 | 2009 | 48 | 0.080 |
Why?
| | Biopsy, Needle | 1 | 2009 | 183 | 0.080 |
Why?
| | Drug Tolerance | 1 | 2009 | 79 | 0.080 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2009 | 61 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 794 | 0.080 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2008 | 13 | 0.080 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2008 | 16 | 0.080 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2008 | 45 | 0.080 |
Why?
| | Blotting, Western | 1 | 2011 | 1153 | 0.080 |
Why?
| | Fellowships and Scholarships | 1 | 2011 | 240 | 0.080 |
Why?
| | Maxilla | 1 | 2007 | 29 | 0.080 |
Why?
| | Databases as Topic | 1 | 2007 | 62 | 0.070 |
Why?
| | Education, Medical, Graduate | 1 | 2011 | 374 | 0.070 |
Why?
| | Quality of Life | 3 | 2024 | 2392 | 0.070 |
Why?
| | Reference Values | 1 | 2008 | 745 | 0.070 |
Why?
| | Arnold-Chiari Malformation | 2 | 1997 | 30 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1486 | 0.070 |
Why?
| | Child | 8 | 2016 | 18556 | 0.070 |
Why?
| | Disease Progression | 1 | 2012 | 2424 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 390 | 0.060 |
Why?
| | Linear Models | 1 | 2007 | 778 | 0.060 |
Why?
| | Risk Assessment | 2 | 2013 | 3004 | 0.060 |
Why?
| | HIV Infections | 1 | 1998 | 2469 | 0.060 |
Why?
| | Child, Preschool | 4 | 2011 | 9176 | 0.060 |
Why?
| | Asthma | 2 | 2016 | 2152 | 0.060 |
Why?
| | Mutation | 1 | 2014 | 3369 | 0.060 |
Why?
| | United States | 3 | 2015 | 12340 | 0.060 |
Why?
| | Fungi | 1 | 2005 | 124 | 0.060 |
Why?
| | Pharyngeal Diseases | 1 | 2003 | 12 | 0.060 |
Why?
| | Drug Resistance, Bacterial | 1 | 2004 | 156 | 0.060 |
Why?
| | Microbial Sensitivity Tests | 1 | 2004 | 299 | 0.060 |
Why?
| | Stroke | 1 | 2012 | 1014 | 0.060 |
Why?
| | Streptococcus pneumoniae | 1 | 2004 | 133 | 0.060 |
Why?
| | Mouth Diseases | 1 | 2003 | 38 | 0.060 |
Why?
| | Acute Disease | 2 | 2016 | 917 | 0.050 |
Why?
| | Head | 1 | 2003 | 87 | 0.050 |
Why?
| | Antifungal Agents | 1 | 2003 | 134 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 1817 | 0.050 |
Why?
| | Equipment Design | 1 | 2004 | 516 | 0.050 |
Why?
| | Vocal Cord Paralysis | 2 | 1998 | 23 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2003 | 197 | 0.050 |
Why?
| | Postoperative Period | 1 | 2022 | 293 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2004 | 386 | 0.050 |
Why?
| | Mitomycin | 1 | 2020 | 27 | 0.050 |
Why?
| | Elective Surgical Procedures | 1 | 2022 | 155 | 0.050 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2001 | 108 | 0.050 |
Why?
| | Genotype | 2 | 2014 | 1843 | 0.040 |
Why?
| | Absorbable Implants | 1 | 2020 | 35 | 0.040 |
Why?
| | Drug Implants | 1 | 2020 | 71 | 0.040 |
Why?
| | Meningioma | 1 | 2001 | 77 | 0.040 |
Why?
| | Signal Transduction | 1 | 2012 | 4525 | 0.040 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 1998 | 2 | 0.040 |
Why?
| | Tracheal Neoplasms | 1 | 1998 | 11 | 0.040 |
Why?
| | Bacterial Infections | 1 | 2000 | 222 | 0.040 |
Why?
| | Laryngeal Neoplasms | 1 | 1998 | 27 | 0.040 |
Why?
| | Nasal Decongestants | 1 | 2018 | 8 | 0.040 |
Why?
| | Larynx | 1 | 1998 | 48 | 0.040 |
Why?
| | Histamine Antagonists | 1 | 2018 | 20 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 127 | 0.040 |
Why?
| | Syndecan-1 | 1 | 2017 | 28 | 0.040 |
Why?
| | Epidemiologic Methods | 1 | 2018 | 73 | 0.040 |
Why?
| | Skin Tests | 1 | 2018 | 137 | 0.040 |
Why?
| | Epistaxis | 2 | 2011 | 11 | 0.040 |
Why?
| | Probiotics | 1 | 2018 | 47 | 0.040 |
Why?
| | Mucus | 1 | 2017 | 55 | 0.040 |
Why?
| | Plasma Cells | 1 | 2017 | 57 | 0.040 |
Why?
| | Length of Stay | 1 | 2022 | 963 | 0.040 |
Why?
| | Complementary Therapies | 1 | 2018 | 73 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2598 | 0.040 |
Why?
| | Carcinoma | 1 | 1998 | 200 | 0.040 |
Why?
| | Neoplasm Invasiveness | 2 | 2013 | 445 | 0.030 |
Why?
| | Physical Examination | 1 | 2018 | 224 | 0.030 |
Why?
| | Immunoglobulin A | 1 | 2017 | 173 | 0.030 |
Why?
| | Occupational Diseases | 1 | 2018 | 129 | 0.030 |
Why?
| | Candidiasis | 1 | 1996 | 58 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 251 | 0.030 |
Why?
| | Perioperative Period | 1 | 2016 | 49 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2017 | 170 | 0.030 |
Why?
| | Chondrocalcinosis | 1 | 1995 | 2 | 0.030 |
Why?
| | Ossification of Posterior Longitudinal Ligament | 1 | 1995 | 2 | 0.030 |
Why?
| | Giant Cell Tumors | 1 | 1995 | 2 | 0.030 |
Why?
| | Odontoid Process | 1 | 1995 | 7 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2016 | 55 | 0.030 |
Why?
| | Chemokines | 1 | 2017 | 214 | 0.030 |
Why?
| | Chondrosarcoma | 1 | 1995 | 12 | 0.030 |
Why?
| | Atlanto-Axial Joint | 1 | 1995 | 15 | 0.030 |
Why?
| | Surgical Wound Dehiscence | 1 | 1995 | 20 | 0.030 |
Why?
| | Chordoma | 1 | 1995 | 13 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2015 | 4449 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2018 | 261 | 0.030 |
Why?
| | Spinal Neoplasms | 1 | 1995 | 29 | 0.030 |
Why?
| | Water Microbiology | 1 | 2016 | 77 | 0.030 |
Why?
| | Thyroid Neoplasms | 1 | 1998 | 261 | 0.030 |
Why?
| | Tracheostomy | 1 | 1996 | 99 | 0.030 |
Why?
| | Spinal Diseases | 1 | 1995 | 45 | 0.030 |
Why?
| | Joint Dislocations | 1 | 1995 | 56 | 0.030 |
Why?
| | Esophageal Neoplasms | 1 | 1998 | 273 | 0.030 |
Why?
| | Biological Products | 1 | 2018 | 172 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 961 | 0.030 |
Why?
| | Joint Diseases | 1 | 1995 | 59 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 174 | 0.030 |
Why?
| | Postoperative Hemorrhage | 1 | 1995 | 78 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1996 | 221 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2016 | 86 | 0.030 |
Why?
| | Sweat | 1 | 2014 | 38 | 0.030 |
Why?
| | Perioperative Care | 1 | 2015 | 127 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 510 | 0.030 |
Why?
| | Allergens | 1 | 2018 | 427 | 0.030 |
Why?
| | Nutritional Status | 1 | 1996 | 287 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2018 | 382 | 0.030 |
Why?
| | Chlorides | 1 | 2014 | 130 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1091 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 2814 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2016 | 492 | 0.030 |
Why?
| | Vestibulocochlear Nerve | 1 | 1993 | 6 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 1995 | 215 | 0.030 |
Why?
| | Facial Nerve | 1 | 1993 | 30 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2017 | 782 | 0.030 |
Why?
| | Phospholipase C beta | 1 | 2013 | 26 | 0.030 |
Why?
| | Cranial Nerve Diseases | 1 | 1993 | 42 | 0.030 |
Why?
| | Transducin | 1 | 2013 | 40 | 0.030 |
Why?
| | Risk Factors | 2 | 2018 | 8714 | 0.030 |
Why?
| | Olfaction Disorders | 1 | 2013 | 49 | 0.030 |
Why?
| | Drug Resistance | 1 | 2013 | 162 | 0.030 |
Why?
| | Angiography | 1 | 2013 | 177 | 0.030 |
Why?
| | Pseudomonas Infections | 1 | 2014 | 190 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2013 | 310 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 2015 | 251 | 0.030 |
Why?
| | Laryngoscopy | 1 | 2013 | 93 | 0.030 |
Why?
| | Gene Expression | 1 | 2017 | 1442 | 0.030 |
Why?
| | Respiratory Tract Diseases | 1 | 2013 | 142 | 0.030 |
Why?
| | Epithelium | 1 | 2013 | 297 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2013 | 621 | 0.030 |
Why?
| | Hematoma | 1 | 2011 | 51 | 0.020 |
Why?
| | Eosinophils | 1 | 2013 | 283 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2011 | 86 | 0.020 |
Why?
| | Animals | 1 | 2012 | 32121 | 0.020 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2013 | 193 | 0.020 |
Why?
| | Survival Rate | 1 | 1995 | 1653 | 0.020 |
Why?
| | Phenylephrine | 1 | 2011 | 75 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 415 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 636 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 137 | 0.020 |
Why?
| | Down Syndrome | 1 | 1995 | 336 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 356 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1547 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 1993 | 1128 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1221 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 1857 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1058 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1177 | 0.020 |
Why?
| | Workload | 1 | 2011 | 132 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1001 | 0.020 |
Why?
| | Societies, Medical | 1 | 2013 | 690 | 0.020 |
Why?
| | Career Choice | 1 | 2011 | 182 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 278 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 1865 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3473 | 0.020 |
Why?
| | Pain | 1 | 2013 | 713 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1995 | 1004 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 945 | 0.020 |
Why?
| | Skin Neoplasms | 1 | 1993 | 760 | 0.020 |
Why?
| | Frontal Sinusitis | 1 | 2005 | 3 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1177 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 927 | 0.020 |
Why?
| | Clinical Competence | 1 | 2011 | 918 | 0.010 |
Why?
| | Lung | 1 | 1996 | 3685 | 0.010 |
Why?
| | Postoperative Care | 1 | 2005 | 222 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 4961 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 4671 | 0.010 |
Why?
| | Adipose Tissue | 1 | 2005 | 553 | 0.010 |
Why?
| | Facial Pain | 1 | 2001 | 12 | 0.010 |
Why?
| | Exophthalmos | 1 | 2001 | 19 | 0.010 |
Why?
| | Masks | 1 | 2001 | 47 | 0.010 |
Why?
| | Nasal Obstruction | 1 | 2001 | 22 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 137 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2001 | 111 | 0.010 |
Why?
| | Headache | 1 | 2001 | 131 | 0.010 |
Why?
| | Laryngectomy | 1 | 1998 | 14 | 0.010 |
Why?
| | Infant | 1 | 2011 | 8002 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 1728 | 0.010 |
Why?
| | Radiosurgery | 1 | 2001 | 298 | 0.010 |
Why?
| | Algorithms | 1 | 1998 | 1493 | 0.010 |
Why?
|
|
Kingdom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|